Skip to main content
. 2016 Nov 4;5(12):e1254854. doi: 10.1080/2162402X.2016.1254854

Figure 2.

Figure 2.

RORγ agonists enhance Type 17 differentiation and cytokine production. (A) RORγ agonist LYC-53772 increased Type 17 cytokines when added to both Th17 and Tc17 differentiation cultures. LYC-53772 vs. vehicle, p < 0.007 for Th17 and p < 0.03 for Th17 and Tc17, respectively. Data represent mean ± SD of biological quadruplicates. (B) LYC-53772 increased the percentage of CD4+IL-17A+ (Th17, left) and CD8+IL-17A+ (Tc17, right) cells with minimal effects on their production of IFNγ (representative flow graph). (C) Elevated IL-17A expression was dependent on RORγ. IL-17A mRNA was assayed by qPCR. Data represent mean ± SD of biological triplicates. (D) RORγ agonist LYC-54143 increased cytokine production in human PBMCs polarized under Type 17 conditions. LYC-54143 vs. vehicle, p < 0.03 for IL-17A, IL-17F, or IL-22, p = 0.5 for IFNγ. Data represent mean ± SD of biological duplicates from one healthy donor. Similar results were obtained for > 4 healthy donors. (E) LYC-53772 decreased the percentage of FOXP3+ cells during differentiation of murine Treg cells. *p = 1.6 × 10−7 LYC-53772 vs. Vehicle. (F) LYC-54143 decreased FOXP3+ cells during Type 17 differentiation of human PBMCs. *p = 0.009, LYC-54143 vs. Vehicle. Data represent mean ± SD of biological triplicates from one healthy donor. Similar results were obtained for three healthy donors. (G) LYC-54143 decreased the percentage of dead murine Type 17 T cells after differentiation and resting for 3 days. *p = 0.0001, LYC-54143 vs. Vehicle. Data represent mean ± SD of biological triplicates. LYC-53772 was used at 10 µM and LYC-54143 at 5 µM.